Key Program Features

  • Proprietary screening platform
  • Preeminent expertise in innate immunity targets
  • Focused on development of broad spectrum antivirals and vaccine adjuvants
  • Rapid progress in identification of novel drug scaffolds - 2 years from hit identification to lead selection

Proprietary AViiD™ Screening Platform

The AViiD™ Screening Platform is a proprietary screening platform developed by Kineta’s scientists to rapidly identify novel innate immune antivirals and vaccine adjuvants

Innate immunity refers to the natural disease fighting defense systems within each of our cells. The AViiD Platform is designed to identify drug compounds that target innate immune pathways including the host cell Interferon Response Factors (IRF) pathways. These pathways are active in most cells in the body and are known to be a critical element of the innate immune response. Our research is focused on the development of broad based antivirals and vaccine adjuvants that target a wide range of high priority infectious viral diseases including:

  • Respiratory syncytial virus (RSV)
  • Influenza
  • Coronaviruses
  • Dengue virus
  • Ebola
  • West Nile Virus
  • Hepatitis B & C

Utilizing the AViiD screening platform, Kineta scientists have successfully identified numerous novel drug classes capable of influencing innate immunity and stimulating natural infection-fighting immune functions. These drug compounds have been shown to be more effective than present therapies, less toxic and less likely to cause viral mutation that leads to more dangerous drug resistant strains. Kineta’s Innate Immune Antiviral and Vaccine Adjuvant programs both offer tremendous potential to address emerging disease threats and global health initiatives.